The continuous innovation of HER2-targeted drugs brings more thorough and precise efficacy, reduces the toxic effects, drug resistance, and recurrence risk, and also provides more diverse options for HER2-positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.